British Columbia Adds Humira Adalimumab to Biosimilar Switching Program
Shots:
- British Columbia and Health Minister Adrian Dix expand the biosimilar switching program to include Humira adalimumab and a new indication for Enbrel etanercept
- The expansion of the biosimilar switching program demonstrated the province’s continued confidence in biosimilars to manage costs and fund innovative new therapies while supporting positive patient outcomes
- BC continues to apply its biosimilar switching policy as new indications become available for marketed biosimilars- and patients taking Enbrel etanercept for the treatment of plaque psoriasis will transition to an etanercept biosimilar during the same period
Ref: Biosimilar | Image: Twitter
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com